SBIR/STTR Research Award

FIBER OPTIC FLUORESCENCE DETECTOR FOR PHOTOSENSITIZER

Award identifier 15ed74816cd697a11a76baa669f6139c821db1f1bc5500ec79cdc6560d0e1bd8Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$0

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
AURORA OPTICS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION: The efficacy and safety of photodynamic therapy (PDT) depends on an understanding of photosensitizer and light biology and dosimetry. Therefore, the ability to accurately determine photosensitizer levels in tumors and at-risk normal tissues is of utmost importance. The goal of this work is to develop and test a prototype system for fluorescence based measurement of photosensitizer uptake in tissue, to improve photodynamic therapy (PDT) dosimetry. The fiber optic system is designed to quantify photosensitizer concentration by detecting a fluorescence intensity signal which minimizes the impact of the tissue optical properties. The bundle is also designed to maximize the signal intensity, allowing quantitation of low concentrations of photosensitizers. Specialized designs have been developed for tissue surface measurement, interstitial measurement and sampling of drawn blood samples. The system is flexible enough to measure either porphyrin-based or phthalocyanine-based photosensitizers, and will specifically be tested in aminolevulinic acid-induced protoporphyrin IX (ALA - PpIX), Photofrin and aluminum disuiphonated phthalocynanine. The system design will be tested in three specific applications where PDT can be successfully commercialized, including (i) veterinary animal tumor therapy, (ii) research in experimental animal tumors, and (iii) adjuvant therapy for human brain tumors after resection. In order to successfully evaluate the system in these different PDT markets, prototype systems will be developed and tested in academic research labs at Dartmouth Medical School and the University of Toronto. The tests will (i) determine how robust the design is, (ii) determine if this dosimetry method improves PDT treatment outcome and (iii) demonstrate safety in human use, prior to commercial development. PROPOSED COMMERCIAL APPLICATION: Not Available

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.